Omentin-1 vs Insulin Glargine
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and Insulin Glargine (Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | Insulin Glargine |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog) |
| Molecular Weight | ~35 kDa | 6063.6 Da |
| Half-Life | hours | About 12-24 hours |
| Amino Acids | 313 | 51 |
| Typical Dose | No approved human dose; research use only | 0.1-0.2 U/kg once daily |
| Route | IV|SC | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 13000 |
| Research Status | Pre-clinical | Approved |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
Insulin Glargine Benefits
- ✓Once-daily basal coverage
- ✓Smooth action profile
- ✓Lower nocturnal hypoglycemia risk
- ✓Improves fasting glucose control
Omentin-1 Dosing
not established|not established
Insulin Glargine Dosing
Inject SC once daily at the same time each day|Titrate every 3-4 days to fasting glucose targets|Can be combined with prandial insulin
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Insulin Glargine Side Effects
- ⚠Hypoglycemia
- ⚠Injection-site reactions
- ⚠Weight gain
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
Insulin Glargine
Clinical and translational studies support its use as a basal comparator because of prolonged absorption and stable glycemic control. It is heavily used in basal-bolus regimen research and insulin-delivery optimization studies.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.